Patents by Inventor Henry Baxter Abajian

Henry Baxter Abajian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptidomimetics inhibiting the oncogenic action of p21 ras
    Patent number: 5910478
    Abstract: The present invention provides peptides, cyclized peptides and peptidomimetics which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: June 8, 1999
    Assignee: Innapharma, Inc.
    Inventors: Joseph J. Hlavka, John Fowler Noble, Henry Baxter Abajian, Andrew S. Kende, Matthew R. Pincus
  • Peptides inhibiting the oncogenic action of p21 ras
    Patent number: 5840683
    Abstract: The present invention provides peptides and cyclized peptides which inhibit the oncogenic and/or transforming activity of the p21 ras protein, pharmaceutical compositions containing at least one of the ras-inhibiting peptides, cyclized peptides and peptidomimetics, and methods for inhibiting the ras-mediated oncogenic and/or transformation process in mammalian cells or tissues.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: November 24, 1998
    Assignee: Innapharma, Inc.
    Inventors: Joseph J. Hlavka, Matthew R. Pincus, John Fowler Noble, Henry Baxter Abajian, Andrew S. Kende
  • Method for treatment of pain
    Patent number: 5721207
    Abstract: An improved method for the treatment of intractable pain is provided by the present invention. The improved method is the intrathecal administration of a therapeutic composition comprising elcatonin and a pharmaceutically acceptable carrier. Intrathecally administered elcatonin produces more potent and prolonged analgesia than elcatonin/calcitonins administered by other routes (e.g., intravenous, intramuscular injection) and/or opiates administered by different routes (including epidural or intrathecal administration).
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: February 24, 1998
    Assignee: Innapharma, Inc.
    Inventors: John Fowler Noble, Henry Baxter Abajian